Earlier this month an approval for Novartis's CDK inhibitor Kisqali gave it a leg up over Eli Lilly's Verzenio. Roche has a number of drugs in the market for breast cancer, but this would be its ...

Each year, two million individuals are diagnosed with breast cancer, resulting in over 685,000 deaths worldwide 1. Although breast cancer is the most commonly diagnosed cancer globally 2, each ...

The randomized phase 3 PATINA trial is the first phase 3 study to show the benefit of cyclin-dependent kinase (CDK ... CDK4/6 inhibitor in combination with endocrine therapy and anti-HER2 drugs ...